Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

IMbrave050 investigators

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences